Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LabVax 3(22)-23 + Sargramostim |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LabVax 3(22)-23 | LabVax | LabVax 3(22)-23 is a vaccine comprising four Labyrinthin-based peptides, which potentially induces an antitumor immune response (J Clin Oncol 41, 2023 (suppl 16; e14660)). | ||
Sargramostim | Leukine | GM-CSF|Prokine |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05101356 | Phase Ib/II | LabVax 3(22)-23 + Sargramostim LabVax 3(22)-23 + Pembrolizumab + Sargramostim | A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma | Recruiting | USA | 0 |